In the past week, there have been more than 260 stocks surveyed by institutions, and Mindray Medical has the largest number of research institutions.

Mindray has 290 institutions surveyed, including 37 fund companies, 17 securities companies, 28 private equity, 12 insurance companies, and 152 overseas institutions. In the survey, the company said that in terms of regions, the international market is expected to continue its rapid growth trend this year, with developing countries, which account for two-thirds of international revenue, leading the growth. In the domestic market, factors that hindered growth last year due to the consolidation of the medical industry, local special bonds and insufficient fiscal funds are expected to usher in an inflection point this year.

Regarding the impact of centralized procurement, the company pointed out that the profitability of Mindray's equipment products is affected by multiple factors such as parts prices and market competition environment, and the impact of centralized procurement projects on profit margins is within a controllable range. Thanks to continuous high R&D investment, insight into clinical needs and integrated innovation capabilities, the company has achieved high-end breakthroughs in most of the available equipment products. The rapid development of artificial intelligence and large language models has also further helped Mindray build a deep moat in the industry, and the company is confident that it will further increase its market share and industry position.

Stocks such as Baili Tianheng, Megmit, and Lens Technology have also been investigated by more than 100 institutions in the past week. In 2024, Baili Tianheng will achieve operating income of 5.823 billion yuan, a year-on-year increase of 936.31%, and net profit attributable to shareholders of listed companies of 3.708 billion yuan, turning losses into profits. The significant increase in the company's operating income was mainly due to the receipt of an irrevocable, non-deductible upfront payment of US$800 million from BMS, a global multinational pharmaceutical company, based on the BL-B01D1 (EGFR×HER3 bispecific antibody ADC) collaboration agreement from its overseas partner, marking the first step in generating revenue from the company's innovative oncology drug portfolio.

At present, the company has carried out more than 30 clinical trials for more than 10 tumor types in China and the United States, including a ×number of phase I/II clinical trials for the treatment of non-small cell lung cancer and advanced solid tumors in the United Statesand 9 Phase III clinical trials (5 of which are included in the Breakthrough Therapy Designation) for the treatment of different cancers in China, among which the Phase III clinical trial in combination with osimertinib in first-line EGFR-mutant locally advanced or metastatic non-small cell lung cancer has completed the enrollment of the first patient. In addition, BL-B01D1 has been in Phase II clinical trials in combination with PD-(L)1 therapy for the first-line treatment of 9 cancer indications (small cell lung cancer, non-small cell lung cancer, nasopharyngeal cancer, head and neck squamous cell carcinoma, esophageal cancer, gastric cancer, colorectal cancer, breast cancer and urothelial cancer).

Under the influence of multiple positives, Baili Tianheng's stock price has continued to rise recently and hit a record high. It is worth mentioning that the company's market value has exceeded the 100 billion yuan mark, reaching 100.35 billion yuan, ranking third in the market value of A-share innovative drugs.

Megmit, which ranks third in the number of research institutions, said that in the context of intensified global trade frictions and changes in the geopolitical environment, the company has shown advantages in overseas market expansion and sales by virtue of its intensive research and forward-looking vision of the power electronics industry, and grasped the opportunity in advance layout. In recent years, with the rapid growth of downstream market demand and the continuous expansion of the company's global market, the company's product orders have maintained a rapid growth trend. In recent years, the expansion of overseas markets has brought new growth points to the company's performance, and at the same time, it has also put forward new requirements for the company's industrial layout. The existing production capacity is difficult to fully meet the rapid growth of market demand in the future. To this end, the company urgently needs to expand the capacity reserve of its main product lines, optimize the capacity structure to meet the rapidly growing global market demand, and provide capacity support for continuous market expansion.

From the perspective of market performance, institutional research stocks fell by 0.47% on average in the past week. Stocks such as consistent konjac, Hailu Heavy Industry, and New Aluminum Times were among the top gainers. On the evening of March 21, the new aluminum era disclosed a major asset restructuring plan, and the company intends to purchase 100% of the shares of Honglian Electronics from 19 counterparties including Chen Wang by issuing shares and paying cash, and raise matching funds. One of the company's core products in the survey was 2μ-level ultra-high-precision shaft, and the technology has been applied to the field of robotics. The main production bases of the target company are Dongguan and Suzhou, and at the same time, the target company also has a production plant in Vietnam, forming the advantage of "material + precision manufacturing" with the new aluminum era, and forming a synergistic effect through technology complementarity, market synergy and global production capacity layout.